Acutaas Chemicals share price
NSE: ACUTAASBSE: 543349Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,215.30.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹25,689 Cr347th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 24 Jul 2026
- 66.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Apr 2026
- 15.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 24 Jul 2026
- 26.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 24 Jul 2026
- 29.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Apr 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,48,10955.1% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 24 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹330 Crdown 23.82%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹75 Crdown 44.15%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 22.7%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 31 Oct | Dec 2024Filed 29 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 30 Jul | Sep 2025Filed 17 Oct | Dec 2025Filed 28 Jan | Mar 2026Filed 30 Apr | Jun 2026Filed 24 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 |
| Net profit | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 15.2% | 16.5% | 20.3% | 21.2% | 23.5% | 27.0% | 31.0% | 22.7% |
Business segments
In the year to Mar 2026 the company reports one business segment, Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 69% of 1,099 trading days since May 2022.
At or below today's level on 93% of 1,150 trading days over the last 5 years.
At or below today's level on 74% of 1,009 trading days since May 2022.
At or below today's level on 31% of 1,203 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +109.8% | +124.5% | −6.6% | 0.1% |
| 3 years | +79.3% | +56.1% | +14.7% | 0.2% |
Mutual funds holding it
164 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 67 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 8
- AddedAdded. Funds that held more shares than at the end of the month before.
- 50
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 62
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal Flexi cap FundMotilal Oswal Mutual Fund | 10,86,350 | 2.65% | ₹356.3 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 9,00,000 | 5.03% | ₹295.1 Cr |
 Kotak Multi Cap FundKotak Mahindra Mutual Fund | 8,26,974 | 0.89% | ₹271.2 Cr |
| Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 4,53,378 | 0.98% | ₹148.7 Cr |
 UTI Small Cap FundUTI Mutual Fund | 4,01,249 | 2.52% | ₹131.6 Cr |
 ITI Small Cap FundITI Mutual Fund | 3,96,614 | 3.55% | ₹130.1 Cr |
| Kotak Balanced Advantage FundKotak Mahindra Mutual Fund | 3,86,016 | 0.76% | ₹126.6 Cr |
| SBI Small Cap FundSBI Mutual Fund | 3,71,566 | 0.30% | ₹121.9 Cr |
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 3,39,010 | 3.18% | ₹111.2 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 3,37,693 | 0.59% | ₹110.7 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Acutaas Chemicals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
 Granules IndiaGRANULES | 21,679 | 32.7 | – | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.22% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 17 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
| 18 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 13 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 18 Sep 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 29 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Analysts
17 Oct · Business
Sep 2026
26 Sep · Management
24 Sep · Business
Acutaas Chemicals share price by year
Each calendar year to 2025.Acutaas Chemicals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,704.90 | +58.7% | 1,872.20 | 940.93 |
| 2024 | 1,074.43 | +91.5% | 1,149.68 | 509.98 |
| 2023 | 561.00 | +16.2% | 684.93 | 432.85 |
| 2022 | 482.68 | −9.6% | 577.10 | 403.33 |
| 2021 | 534.20 | – | 697.15 | 433.95 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 3,219.40 | 3,236.70 | 3,085.00 | 3,137.70 | 3,126.62 | 3,48,109 | 55.1% |
| 22 Oct 2026 | 3,152.10 | 3,253.00 | 3,130.60 | 3,215.30 | 3,208.59 | 3,09,343 | 52.9% |
| 21 Oct 2026 | 3,262.90 | 3,269.80 | 3,100.00 | 3,152.40 | 3,170.86 | 3,04,749 | 48.1% |
| 19 Oct 2026 | 3,275.00 | 3,354.40 | 3,234.10 | 3,253.40 | 3,298.70 | 5,57,451 | 30.5% |
| 16 Oct 2026 | 3,132.50 | 3,219.00 | 3,116.60 | 3,206.00 | 3,180.50 | 4,82,617 | 45.2% |
| 15 Oct 2026 | 3,179.00 | 3,192.00 | 3,125.10 | 3,132.50 | 3,152.16 | 2,11,008 | 54.9% |
| 14 Oct 2026 | 3,176.90 | 3,203.50 | 3,115.10 | 3,160.50 | 3,163.78 | 3,47,396 | 51.9% |
| 13 Oct 2026 | 3,160.00 | 3,206.00 | 3,062.40 | 3,176.70 | 3,117.28 | 2,52,189 | 49.7% |
| 12 Oct 2026 | 3,160.00 | 3,199.80 | 3,130.00 | 3,144.10 | 3,157.84 | 1,29,650 | 47.7% |
| 9 Oct 2026 | 3,059.00 | 3,190.00 | 3,031.10 | 3,160.60 | 3,138.41 | 3,65,667 | 38.9% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Apr 2025 | Split | 0.5000 | Each share became 2. |
About Acutaas Chemicals
Acutaas Chemicals Limited is a specialty chemicals company with its registered office at GIDC Sachin, Surat, in Gujarat. It runs four business verticals: advanced pharmaceutical intermediates, semiconductor chemicals, battery chemicals and commodity chemicals. It began in 2004 as a partnership firm and was incorporated in 2007.
The pharmaceutical intermediates business started by supporting an innovator molecule and then expanded into generic pharmaceutical intermediates. It also works with customers as a contract manufacturer and developer (CMO/CDMO). Semiconductor chemicals come from Baba Fine Chemicals in Greater Noida, Uttar Pradesh, a partnership firm in which the company holds 55% of the partnership rights. It makes photoresist chemicals. The battery chemicals vertical makes the electrolyte additives Vinylene Carbonate and Fluoroethylene Carbonate at Jhagadia, where the first phase was inaugurated on 19 January 2026.
Manufacturing sites are at Sachin, Ankleshwar and Jhagadia in Gujarat, and at Greater Noida. A fifth site is under construction at Gongju in South Korea. It belongs to Indichem Inc., a joint venture with South Korea's J & Materials Co. Ltd., in which the company's wholly owned subsidiary Acutaas Advance Material Limited holds 75%. The company has more than 1,000 employees and a research team of more than 130 people.
It acquired the Ankleshwar and Jhagadia units from Gujarat Organics Ltd. in 2021, and Baba Fine Chemicals in 2023, which marked its entry into semiconductor chemicals. Its founder, Naresh Patel, is its chairman and managing director.
- Legal name
- Acutaas Chemicals Limited
- NSE symbol
- ACUTAAS
- BSE code
- 543349
- ISIN
- INE00FF01025
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2021
- Face value
- ₹5
- Former symbols
- AMIORG
- CIN
- L24100GJ2007PLC051093
- Corporate identity number, the registrar of companies' code for it